Chorea-Acanthocytosis (ChAc)
Introduction
Chorea Acanthocytosis (Chac) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Chorea-Acanthocytosis (ChAc) is an ultra-rare autosomal recessive neurodegenerative disorder characterized by a combination of progressive movement abnormalities—most prominently chorea (involuntary, jerky, dancelike movements)—and the presence of abnormally shaped red blood cells called acanthocytes (cells with spiky, irregular membranes). This condition, belonging to the neuroacanthocytosis syndrome family, typically emerges in early to mid-adulthood and follows a progressive course over 10-30 years, ultimately leading to significant disability and cognitive decline.[@choreaacanthocytosis] [@chorein]
The disorder results from mutations in the VPS13A gene (also known as CHAC), which encodes the protein chorein—a protein involved in intracellular membrane trafficking and organelle dynamics. The loss of functional chorein leads to both the characteristic red blood cell abnormalities and progressive neurodegeneration, particularly affecting the basal ganglia regions of the brain.[@chorein] [@chronic]
...Chorea-Acanthocytosis (ChAc)
Introduction
Chorea Acanthocytosis (Chac) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Chorea-Acanthocytosis (ChAc) is an ultra-rare autosomal recessive neurodegenerative disorder characterized by a combination of progressive movement abnormalities—most prominently chorea (involuntary, jerky, dancelike movements)—and the presence of abnormally shaped red blood cells called acanthocytes (cells with spiky, irregular membranes). This condition, belonging to the neuroacanthocytosis syndrome family, typically emerges in early to mid-adulthood and follows a progressive course over 10-30 years, ultimately leading to significant disability and cognitive decline.[@choreaacanthocytosis] [@chorein]
The disorder results from mutations in the VPS13A gene (also known as CHAC), which encodes the protein chorein—a protein involved in intracellular membrane trafficking and organelle dynamics. The loss of functional chorein leads to both the characteristic red blood cell abnormalities and progressive neurodegeneration, particularly affecting the basal ganglia regions of the brain.[@chorein] [@chronic]
Key clinical features include: [@subthalamic]
- Progressive choreiform movements affecting limbs, face, and trunk
- Orofacial dyskinesias (involuntary lip and tongue movements)
- Psychiatric symptoms including cognitive decline and behavioral changes
- Acanthocytosis visible on peripheral blood smear
- Elevated creatine kinase levels in approximately 50% of patients
Diagnosis requires clinical evaluation, genetic testing for VPS13A mutations, and exclusion of similar disorders such as Huntington's disease. Management is primarily supportive, focusing on symptom control with medications such as tetrabenazine for chorea, antipsychotics, and multidisciplinary care including physical, occupational, and speech therapy.[@chronic] [@proceedings]
Chorea-Acanthocytosis represents an important model for understanding basal ganglia degeneration and the relationship between membrane protein trafficking and neuronal survival. Research into VPS13A function continues to provide insights relevant to Huntington's disease and other neurodegenerative conditions. [^6]
Epidemiology
Chorea-Acanthocytosis is extremely rare: [^7]
- Prevalence: Approximately 1-5 per million individuals
- Inheritance: Autosomal recessive
- Age of onset: Typically between ages 20-40
- Gender: Affects both males and females equally
- Ethnicity: No specific ethnic predilection; cases reported worldwide
Due to its rarity, the true prevalence may be underestimated. Many cases may be misdiagnosed as Huntington's disease or other movement disorders.[@chorein] [^8]
Genetics and Pathophysiology
Genetic Basis
Chorea-Acanthocytosis is caused by mutations in the
VPS13A gene (also called CHAC) on chromosome 9q21. This gene encodes the protein chorein, which is involved in:
- Protein trafficking between intracellular organelles
- Membrane dynamics
- Cytoskeletal organization
Over 60 pathogenic mutations have been identified, including:
- Nonsense mutations (premature stop codons)
- Missense mutations
- Splice site mutations
- Large deletions
Protein Dysfunction
Chorein is localized to:
- Endoplasmic reticulum
- Golgi apparatus
- Mitochondria
- Plasma membrane
Loss of chorein function leads to:
Abnormal erythrocyte shape (acanthocytosis)
Neuronal dysfunction and degeneration
Progressive movement disorderNeuropathology
- Striatal degeneration: Loss of medium spiny [neurons](/entities/neurons) in the caudate nucleus and putamen
- Cerebral atrophy: Particularly in basal ganglia regions
- Neuronal loss and gliosis in affected brain regions
- Abnormal protein inclusions in some cases
Clinical Features
Core Movement Disorders
Chorea:
- Involuntary, jerky, dancelike movements
- Affects limbs, trunk, and face
- Often persistent and disabling
- May be subtle initially
Orofacial Dyskinesias:
- Involuntary lip-smacking, tongue protrusion
- Feeding difficulties
- Speech and swallowing problems (dysarthria, dysphagia)
Parkinsonism:
- Bradykinesia (slowness of movement)
- Rigidity
- Resting tremor (less common)
Dystonia:
- Involuntary muscle contractions
- Abnormal postures
- May affect neck, limbs
Psychiatric and Cognitive Symptoms
- Cognitive decline: Progressive dementia in later stages
- Behavioral changes: Irritability, aggression, depression
- Anxiety and obsessive-compulsive symptoms
- Psychosis (less common)
Systemic Features
- Acanthocytosis: 10-90% of red blood cells affected
- Elevated creatine kinase (CK): Muscle involvement
- Myopathy: Muscle weakness in some patients
- Seizures: Approximately 30% of patients
Diagnosis
Clinical Diagnostic Criteria
Progressive chorea with orofacial involvement
Acanthocytosis on peripheral blood smear (>10% acanthocytes)
Normal frataxin gene (to exclude Friedreich's ataxia)
Normal very-long-chain fatty acids (to exclude adrenoleukodystrophy)
Absence of Huntington's disease mutationLaboratory Findings
- Blood smear: Acanthocytosis (10-90% abnormal RBCs)
- Serum CK: Elevated in 50% of patients
- Liver enzymes: May be mildly elevated
- Genetic testing: Biallelic VPS13A mutations confirmed by sequencing
Neuroimaging
- MRI brain:
- Caudate nucleus atrophy
- Putaminal changes
- Cerebral cortical atrophy (later stages)
- CT brain: May show basal ganglia calcifications
- SPECT/PET: Reduced metabolism in basal ganglia
Differential Diagnosis
- Huntington's disease (HD)
- McLeod syndrome
- Friedreich's ataxia
- Wilson's disease
- Basal ganglia calcification disorders
- Other neuroacanthocytosis syndromes
Treatment
Disease-Modifying Therapy
No disease-modifying treatment exists. Management is symptomatic and supportive.
Movement Disorder Treatment
Chorea:
- Tetrabenazine: Often first-line
- Deutetrabenazine: Longer half-life
- Valbenazine: Once-daily option
- Antipsychotics: Haloperidol, olanzapine, risperidone
Parkinsonism:
- Levodopa/carbidopa: May help some patients
- Dopamine agonists: Pramipexole, ropinirole
Dystonia:
- Botulinum toxin injections
- Anticholinergics (trihexyphenidyl)
- Muscle relaxants (baclofen)
Psychiatric Symptoms
- SSRIs for depression, anxiety
- Atypical antipsychotics for psychosis
- Mood stabilizers as needed
Supportive Care
- Physical therapy: Maintain mobility, prevent contractures
- Occupational therapy: Assist with daily activities
- Speech therapy: Address dysarthria and dysphagia
- Nutritional support: May require feeding tubes in advanced cases
- Seizure control: Standard antiepileptic medications
Prognosis
- Disease progression: Typically 10-30 years
- Cause of death: Aspiration pneumonia, complications of dysphagia
- Cognitive decline: Progressive, leading to severe dementia
- Motor disability: Gradually worsens, often requiring wheelchair
Relationship to Neurodegeneration
Chorea-Acanthocytosis provides important insights into neurodegenerative mechanisms:
- Basal ganglia degeneration: Shared pathophysiology with Huntington's disease
- Protein trafficking defects: Links to other neurodegenerative disorders
- Erythrocyte abnormalities: Unique model of membrane dysfunction
- [Huntingtin](/proteins/huntingtin-protein) protein interactions: Research suggests VPS13 proteins may interact with [huntingtin](/genes/htt)
- [Autophagy](/entities/autophagy) and mitophagy: Chorein involved in cellular clearance mechanisms
Understanding VPS13A function may provide insights into:[@chronic]
- Huntington's disease pathogenesis
- Other neuroacanthocytosis syndromes
- General mechanisms of neurodegeneration
Research Directions
Current research focuses on:
- Understanding chorein function and normal biology
- Developing VPS13A gene therapy
- Identifying biomarkers for disease progression
- Neuroprotective strategies
- Stem cell-based therapies
See Also
- [Huntington's Disease](/diseases/huntingtons)
- [McLeod Syndrome](/diseases/mcleod-syndrome)
- [Neuroacanthocytosis Syndromes](/diseases/neuroacanthocytosis-syndromes)
- [Basal Ganglia Degeneration](/mechanisms/basal-ganglia-degeneration)
- [Movement Disorders](/mechanisms/movement-disorders)
Background
The study of Chorea Acanthocytosis (Chac) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
- [Chorea-acanthocytosis with homozygous variant of VPS13A gene concomitant with intermediate expansion of JPH3 gene: Who is the villain?](https://pubmed.ncbi.nlm.nih.gov/41610477/) (2026 Mar) - Parkinsonism & related disorders
- [Chorein Regulates Key Osteoblast Genes in UMR-106 Cells.](https://pubmed.ncbi.nlm.nih.gov/41171582/) (2026 Mar) - Cell biochemistry and biophysics
- [Chronic Granulomatous Disease.](https://pubmed.ncbi.nlm.nih.gov/22876374/) (1993) -
- [Subthalamic Deep Brain Stimulation for Chorea-Acanthocytosis: A Single-Center Case Series.](https://pubmed.ncbi.nlm.nih.gov/41518361/) (2026 Jan 10) - Neuromodulation : journal of the International Neuromodulation Society
- [Proceedings of the 12(th) International Meeting on Neuroacanthocytosis, Cohen Syndrome, and Other VPS13-Related Disorders.](https://pubmed.ncbi.nlm.nih.gov/41522673/) (2026) - Tremor and other hyperkinetic movements (New York, N.Y.)
References
[Unknown, Chorea-acanthocytosis with homozygous variant of VPS13A gene concomitant with intermediate expansion of JPH3 gene: Who is the villain? (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41610477/)
[Unknown, Chorein Regulates Key Osteoblast Genes in UMR-106 Cells (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41171582/)
[Unknown, Chronic Granulomatous Disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/22876374/)
[Unknown, Subthalamic Deep Brain Stimulation for Chorea-Acanthocytosis: A Single-Center Case Series (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41518361/)
[Unknown, Proceedings of the 12(th) International Meeting on Neuroacanthocytosis, Cohen Syndrome, and Other VPS13-Related Disorders (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41522673/)